NOVATO, Calif. - Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a $2.58 billion market cap biotechnology company currently trading near its 52-week low of $25.81, announced Thursday it has completed enrollment for its Phase 3 Aspire study evaluating GTX-102 (apazunersen) as a treatment for Angelman syndrome, with approximately 129 participants ages four to 17. According to InvestingPro data, seven analysts have recently revised their earnings expectations upward for the upcoming period. The study, which began enrollment in December 2024, reached full recruitment in just seven months. Participants all have a genetically confirmed diagnosis of full maternal UBE3A gene deletion, according to the company's press release statement. The randomized trial will evaluate GTX-102 administered via intrathecal injection against a sham comparator over 48 weeks.